Browse all 651 ETFs by category, no search needed
Global 185
US market 62
Country 93
Core UCITS 15
Sector 103
Style & factor 111
Theme 45
Dividend 37
Franklin Genomic Advancements (HELX)Overvalued or undervalued?
Look-through valuation · Theme · Expense ratio 0.50 % · ISIN US35473P5200
Price history (since 2020)
Monthly close since 2020. Price shows performance, the valuation verdict is in the look-through above.
Top holdings
| Holding | Weight | vs fair value | Quality |
|---|---|---|---|
| Natera Inc NTRA | 10.0 % | −94.3 % | 37 |
| Guardant Health Inc GH | 9.9 % | n/a | n/a |
| Krystal Biotech Inc KRYS | 5.4 % | +12.9 % | 71 |
| Adaptive Biotechnologies Corp ADPT | 4.8 % | n/a | n/a |
| Twist Bioscience Corp TWST | 4.5 % | n/a | n/a |
| Ligand Pharmaceuticals Incorporated LGND | 4.4 % | −69.1 % | 56 |
| BridgeBio Pharma Inc BBIO | 2.9 % | n/a | n/a |
| Travere Therapeutics Inc TVTX | 2.8 % | −87.2 % | 35 |
| Medpace Holdings Inc MEDP | 2.7 % | +10.0 % | 86 |
| Vertex Pharmaceuticals Inc VRTX | 2.6 % | +10.0 % | 79 |
| Corteva Inc CTVA | 2.4 % | −64.6 % | 70 |
| United Therapeutics Corporation UTHR | 2.3 % | +62.2 % | 72 |
| Eli Lilly and Company LLY | 2.3 % | −31.2 % | 69 |
| Regeneron Pharmaceuticals Inc REGN | 2.1 % | +56.1 % | 72 |
| Tempus AI, Inc. Class A Common Stock TEM | 2.1 % | n/a | n/a |
| Repligen Corporation RGEN | 2.0 % | −56.4 % | 67 |
| GRAIL, LLC GRAL | 1.6 % | n/a | n/a |
| Argen-X ARGX | 1.6 % | n/a | n/a |
| CareDx Inc CDNA | 1.4 % | −77.2 % | 68 |
| Charles River Laboratories CRL | 1.4 % | −56.7 % | 59 |
| Neurocrine Biosciences Inc NBIX | 1.4 % | +55.0 % | 71 |
| Jazz Pharmaceuticals PLC JAZZ | 1.4 % | +95.9 % | 58 |
| BioNTech SE BNTX | 1.2 % | −35.4 % | 53 |
| 10X Genomics Inc TXG | 1.2 % | −71.3 % | 66 |
| IQVIA Holdings Inc IQV | 1.1 % | +10.4 % | 57 |
Fair value and quality per position come from the same valuation as our stock pages. Showing the 25 largest of 50 disclosed positions. "n/a" means the position is not (yet) in our stock universe and does not enter the average.
The 10 most cheaply valued ETFs
Measured against the look-through fair value of the holdings (sufficiently covered funds only). Green means below fair value, red above. Not financial advice.
- 1 CHIU Global X MSCI China Utilities ETF +87.2 % below FV
- 2 FXI iShares China Large-Cap ETF +57.2 % below FV
- 3 FCFY First Trust S&P 500 Diversified Free Cash Flow ETF +43.7 % below FV
- 4 MCHI iShares MSCI China ETF +41.9 % below FV
- 5 ITB iShares U.S. Home Construction ETF +31.4 % below FV
- 6 TAN Invesco Solar ETF +26.0 % below FV
- 7 C003 Amundi Index Solutions - Amundi DivDAX I UCITS ETF EUR Distributing +19.4 % below FV
- 8 FDNI First Trust Dow Jones International Internet ETF +19.3 % below FV
- 9 ESPO VanEck Video Gaming and eSports ETF +18.3 % below FV
- 10 XIDV Franklin International Dividend Booster Index ETF +17.9 % below FV
Frequently asked about HELX
Is HELX overvalued?
What is the fair value of HELX?
How do you calculate the fair value of an ETF?
Which stocks drive the valuation of HELX?
What is the expense ratio of HELX?
How we value this ETF
An ETF has no fair value of its own like a single stock. We build it bottom up: every holding has a fair value and a quality score on our pages. Weighted by portfolio share, that gives Franklin Genomic Advancements ETF an average of how cheap or expensive its companies currently sit versus fair value, and how high their average quality is.
As of: Sep 25, 2026
The look-through is a computed summary of public fundamentals and is no substitute for your own research.